Inhibition of lncRNA MAAT Controls Multiple Types of Muscle Atrophy by cis- and trans-Regulatory Actions

Li, Jin; Yang, Tingting; Tang, Haifei; Sha, Zhao; Chen, Rui; Chen, Lei; Yu, Yan; Rowe, Glenn C.; Das, Saumya; Xiao, Junjie

doi:10.1016/j.ymthe.2020.12.002

Cited by 27 publications

(29 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia can increase the risk of weakness, falls and fractures, decrease the quality of life, even the ability to live independently, and increase the infection rate, and mortality rate in patients. Sarcopenia is associated with CVDs, diabetes, renal insufficiency, cancer, cognitive impairment, and even with the prognosis of some diseases ( 19 – 22 ).…”

Section: Sarcopeniamentioning

confidence: 99%

Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview

Zhang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

With the advent of population aging, aging-related diseases have become a challenge for governments worldwide. Sarcopenia has defined as a clinical syndrome associated with age-related loss such as skeletal muscle mass, strength, function, and physical performance. It is commonly seen in elderly patients with chronic diseases. Changes in lean mass are common critical determinants in the pathophysiology and progression of cardiovascular diseases (CVDs). Sarcopenia may be one of the most important causes of poor physical function and decreased cardiopulmonary function in elderly patients with CVDs. Sarcopenia may induce CVDs through common pathogenic pathways such as malnutrition, physical inactivity, insulin resistance, inflammation; these mechanisms interact. In this study, we aimed to investigate the relationship between sarcopenia and CVDs in the elderly. Further research is urgently needed to understand better the relationship, pathophysiology, clinical presentation, diagnostic criteria, and mechanisms of sarcopenia and CVDs, which may shed light on potential interventions to improve clinical outcomes and provide greater insight into the disorders above.

show abstract

Section: Sarcopeniamentioning

confidence: 99%

Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview

Zhang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Targeting lncMAAT is a promising strategy for preventing muscle atrophy induced by a variety of factors. 126 Together, our findings bring hope for the treatment of muscle atrophy.…”

Section: Ncrnas As Common Targets For Muscle Atrophymentioning

confidence: 63%

Non-coding RNA basis of muscle atrophy

Liu

Deng

Qiu

et al. 2021

Molecular Therapy - Nucleic Acids

Self Cite

View full text Add to dashboard Cite

Muscle atrophy is a common complication of many chronic diseases including heart failure, cancer cachexia, aging, etc. Unhealthy habits and usage of hormones such as dexamethasone can also lead to muscle atrophy. However, the underlying mechanisms of muscle atrophy are not completely understood. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), play vital roles in muscle atrophy. This review mainly discusses the regulation of ncRNAs in muscle atrophy induced by various factors such as heart failure, cancer cachexia, aging, chronic obstructive pulmonary disease (COPD), peripheral nerve injury (PNI), chronic kidney disease (CKD), unhealthy habits, and usage of hormones; highlights the findings of ncRNAs as common regulators in multiple types of muscle atrophy; and summarizes current therapies and underlying mechanisms for muscle atrophy. This review will deepen the understanding of skeletal muscle biology and provide new strategies and insights into gene therapy for muscle atrophy.

show abstract

“…Numerous identified lncRNAs are transcribed by RNA polymerase II. They may be 5′-capped and polyadenylated, usually located in the nuclear and cytoplasmic [30][31][32]. The lncRNA-related data have been reported and annotated in LncBase and other databases.…”

Section: The Emerging Roles Of Competing Endogenous Rna (Cerna) In Hccmentioning

confidence: 99%

The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide due to its high degree of malignancy, high incidence, and low survival rate. However, the underlying mechanisms of hepatocarcinogenesis remain unclear. Long non coding RNA (lncRNA) has been shown as a novel type of RNA. lncRNA by acting as ceRNA can participate in various biological processes of HCC cells, such as tumor cell proliferation, migration, invasion, apoptosis and drug resistance by regulating downstream target gene expression and cancer-related signaling pathways. Meanwhile, lncRNA can predict the efficacy of treatment strategies for HCC and serve as a potential target for the diagnosis and treatment of HCC. Therefore, lncRNA serving as ceRNA may become a vital candidate biomarker for clinical diagnosis and treatment. In this review, the epidemiology of HCC, including morbidity, mortality, regional distribution, risk factors, and current treatment advances, was briefly discussed, and some biological functions of lncRNA in HCC were summarized with emphasis on the molecular mechanism and clinical application of lncRNA-mediated ceRNA regulatory network in HCC. This paper can contribute to the better understanding of the mechanism of the influence of lncRNA-mediated ceRNA networks (ceRNETs) on HCC and provide directions and strategies for future studies.

show abstract

Inhibition of lncRNA MAAT Controls Multiple Types of Muscle Atrophy by cis- and trans-Regulatory Actions

Cited by 27 publications

References 71 publications

Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview

Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview

Non-coding RNA basis of muscle atrophy

The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma

Contact Info

Product

Resources

About